Recombinant adenovirus is one of the most efficient gene delivery vehicles for both in vitro and in vivo protein expression due to the high infection efficiency and subsequent yield of recombinant protein. Adenoviruses can infect a broad range of cells, including dividing and non-dividing cells, stem cells and primary cells, and are particularly useful for infecting cell lines that have low transfection efficiency with liposome based methods.

Adenoviruses do not integrate their genome into the host system and therefore do not risk activating or inactivating host genes. Expression of the recombinant protein of interest is detectable within 24 hours post infection and is transient in nature. The expression will persist as long as the viral genome is not degraded, which is around 1-2 weeks depending on the cell type. Longer expression can be observed in slow dividing cells such as neurons.

As a world leader in adenoviral technology, abm has developed a variety of different adenoviral expression systems which can be used to temporarily alter expression within a sample of cells or to moniter gene expression using reporter genes. These systems allow other scientists to produce their own adenoviruses.

Key features:

• Biosafety: Replication-incompetent (-E1/-E3) human adenovirus type 5 (Ad5).
• Almost 100% gene delivery in most cell types; very few cell lines cannot be infected.
• Can be used for in vivo or in vitro recombinant protein expression.
• Non-integrating; No alteration to host genome.